Comment on The company that took on Martin Shkreli's drug price hikes has a new target (IMMY, RTRX)

The company that took on Martin Shkreli's drug price hikes has a new target (IMMY, RTRX)

AP Photo/Richard DrewMark Baum thrust himself into drug-price debate last year when he offered to make a $1 version of Daraprim, the toxoplasmosis treatment that Martin Shkreli was selling for $750 a pill. Now, Baum has a new target in his sights. Called Thiola, the drug also treats a rare disease and is owned by a company that hiked its price substantially – by 2000% in 2014 –without any real justification. And, in fact, the architect of Thiola's price hike was none other than Shkreli.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News